SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline (JOBS) to Pay Actelion Ltd. up to $3.3 Billion for Drug Rights

July 14, 2008 | 
1 min read

ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.

Alliances Mergers & acquisitions Europe
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Pipeline
Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two hands shaking while another hand gently grips a wrist
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Contract Cancellation, Agreement Termination Concept. Couple of Tiny Male Characters Tearing Huge Paper Sheet with Terminated Contract. Businessmen at Workspace. Cartoon People Vector Illustration
Gene therapy
Vertex Severs Liver Gene Therapies Partnership With Verve
February 27, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vector illustration of a hand holding both a businesswoman and a businessman, symbolizing corporate support, care, and equality. Ideal for employee guarantee and security materials
C-suite
GSK CEO Emma Walmsley Gets Pay Bump To Align With Pharma Peers
February 27, 2025
 · 
2 min read
 · 
Annalee Armstrong